SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Blood Test, Blood, Medical Sample, Test Tube
Drug Development
Roche, ADC and Caribou Get the Blood Pumping at EHA
The European Hematology Association’s 2022 Hybrid Congress is in full swing in Vienna, Austria and will feature the newest and most promising developments in blood cancer research.
June 10, 2022
 · 
5 min read
 · 
Tristan Manalac
Degron Co-founder and CEO Lily Zou, Ph.D/courtesy
Business
Degron Therapeutics Launches into Sizzling Hot Protein Degradation Space
Degron Therapeutics, based in Shanghai, announced Thursday that it has secured $22 million in Series A financing for its unique molecular glue-based targeted protein degradation platform GlueXplorer.
June 9, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Annexon Engages the Target, Sees Stabilization in Phase II Huntington’s Trial
Annexon released final data from an open-label phase II clinical trial, showing that its drug candidate ANX005 safely stabilized disease progression in patients with Huntington’s disease.
June 8, 2022
 · 
3 min read
 · 
Tristan Manalac
Courtesy of Getty Images
Drug Development
Lilly’s Mounjaro Bests Novo’s Diabetes Drugs in Comparison Study
The Phase I mechanism of action study, showing that Lilly’s injectable Mounjaro (tirzepatide) induces greater weight loss than placebo and Novo Nordisk’s semaglutide in adults with type 2 diabetes.
June 7, 2022
 · 
2 min read
 · 
Tristan Manalac
A Novartis building under a blue sky/courtesy of C
Drug Development
Novartis Combo could be New Standard of Care for Pediatric Glioma Patients
Results of a Phase II/III study showed that patients who were given Tafinlar plus Mekinist saw an overall response rate of 47% vs. 11% for those who received standard chemotherapy only.
June 7, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Real World Study Demonstrates Consistent Survival for Gilead’s Yescarta Across Race/Ethnicity
The study revealed that Yescarta was both safe and effective in adult patients regardless of race and ethnicity.
June 6, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More